Ionis Pharmaceuticals IONS Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's investment proceeds?
- Ionis Pharmaceuticals (IONS) reported investment proceeds of $752.82M in Q1 2026.
- How has Ionis Pharmaceuticals's investment proceeds changed year-over-year?
- Ionis Pharmaceuticals's investment proceeds increased by 52.2% year-over-year, from $494.76M to $752.82M.
- What is the long-term trend for Ionis Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's investment proceeds has grown at a 6.0% compound annual growth rate (CAGR), from $1.34B to $1.7B.
- What does investment proceeds mean?
- Cash received from selling or maturing financial investments.
- How do you interpret investment proceeds?
- High inflows often signal a need for liquidity to fund operations or capital expenditures, or the realization of gains on investment portfolios.
- How does investment proceeds compare across companies?
- Standard line item for companies managing investment portfolios.